This document contains a slide deck presentation on hemp oil and the endocannabinoid system. It discusses the history of research on cannabis, the endogenous cannabinoid system, and how various interventions can upregulate this system. Throughout, it stresses that the information is for educational purposes only and that no claims are being made about Zilis products treating, preventing, or curing any diseases.

1. Louis B. Cady, MD, FAPA – CEO & Founder – Cady Wellness InstituteLouis B. Cady, MD, FAPA – CEO & Founder – Cady Wellness Institute
Adjunct Clinical Lecturer – Indiana University School of Medicine
Department of Psychiatry
Functional & Integrative Medicine – Evansville, Indiana
Hemp Oil: What Can It Do For You?
August 22, 2018
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

2. A note for the viewer – please read carefully.
• The slide presentation in this “deck” was presented as an educational
lecture on April 6, 2018 in Evansville, Indiana. I have had several
requests for the slides.
• All slides in this deck should be looked at as informational ONLY. Any
benefit for the use of these products is ONLY due to their ability to
support the structure and function of the human body.
• This deck may not be downloaded, stored, or modified in any way
whatsoever.
This slide deck is not approved by the FDA. No Zilis product can be represented
to treat, prevent, mitigate, or cure any disease. They are used ONLY for the
structure and support of the body – specifically, the endocannabinoid system.

3. Getting high on cannabis makes you less likely to work hard for
money, study says – The Independent Sept 1, 2016
So why did God put a receptor for THC in our brains?
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

4. This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

5. Eliassen AH, et al. Circulating Carotenoids and Risk of Breast Cancer: Pooled Analysis of Eight
Prospective Studies. J Natl Cancer Inst. 2012 Dec 19;104(24):1905-16. doi: 10.1093/jnci/djs461.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

6. MVI – supports the structure & function
• B12 - 1,000% (as 60 MICROgrams cyanocobalamin)
• B6 - 500%
• Folic acid/folate - 150%
• Magnesium 76% (as 300 Mg amino acid chelate)
• Zinc 100% (15 mg as zinc chelate)
• Selenium 200% (L-selenomethionine & NaSeO3)
• Iodine 76%
• Chromium 166% blood sugar control!
• Vitamin C 834%
• Vitamin A 300% (83% as Beta carotene and plant extracts
• Vitamin E 666% (200 IU Vitamin E, d-alpha tocopherol, tocotrienols
HOMOCYSTEINE LOWERING
MOOD IMPROVING
Testosterone raising!
Boosts thyroid production!

8. • Raphael Mechoulam, Ph.D.
• Professor of Medicinal Chemistry at
Hebrew University of Jerusalem
• He/research group chemically
synthesized all of the major plant
cannabinoids ( delta-9TCH,
cannabidiol, cannabigerol
• First isolation of the first
endocannabinoid – Anandamide
• 2-AG was soon discovered by
Shimon Ben-Shabat, one of his Ph.D.
students.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They are
used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

9. History of Cannabidiol, Endocannabinoid
system, etc.
• Hashish I. The structure of cannabidiol –
Mechoulam, Shvo, 1963
• Hashish. IV. The isolation and structure of
cannabinolic and cannabigerolic acids. 1964
• Delta-9 THC was synthesized. 1965
• “The effect of cannabidiol on mouse hepatic
microsomal anandamide metabolism. 1993 – first
paper on “endocannabinoid system.”This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

10. “Clinical endocannabinoid deficiency (CECD) can this
concept explain therapeutic benefits of cannabis in
migraine, fibromyalgia, IBS, and other treatment resistant
conditions?”
• Yes!
• First published by EB Russo in 2004
• “Migraine, fibromyalgia, IBS, and related
conditions…suggest an underlying clinical
endocannabinoid deficiency that may be suitably
treated with cannabinoid medicines.”
Neuro Endocrinol Lett. 2004 Feb-Apr;25(1-2):31-9.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

11. 4,382 results – Feb 2, 2018 6:26 am4,382 results – Feb 2, 2018 6:26 am
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

12. 4,591 results – August 19, 20184,591 results – August 19, 2018
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

13. Study: evaluate CB1 ligands + other agents “that possess
antidepressant potential.”
CONCLUSIONS: “The simultaneous modulation of the
cannabinoid system and supplementation of magnesium
or zinc produce at least additive antidepressant-like
effect.”
Study: evaluate CB1 ligands + other agents “that possess
antidepressant potential.”
CONCLUSIONS: “The simultaneous modulation of the
cannabinoid system and supplementation of magnesium
or zinc produce at least additive antidepressant-like
effect.”This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

14. The results of the present study suggest that CB1r,
CB2r, and MAGL are closely related to the
neuropathological processes of PD. Therefore, the
pharmacological modulation of these targets
could represent a new potential therapeutic tool
for the management of PD.
The results of the present study suggest that CB1r,
CB2r, and MAGL are closely related to the
neuropathological processes of PD. Therefore, the
pharmacological modulation of these targets
could represent a new potential therapeutic tool
for the management of PD.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

15. Smith SC. Neuro Endocrinol Lett.
2014;35(3):198-201.
Smith SC. Neuro Endocrinol Lett.
2014;35(3):198-201.
CONCLUSION: Subsequent research has confirmed that underlying
endocannabinoid deficiencies indeed play a role in migraine,
fibromyalgia, irritable bowel syndrome and a growing list of other
medical conditions. Clinical experience is bearing this out. Further
research and especially, clinical trials will further demonstrate the
usefulness of medical cannabis. As legal barriers fall and scientific
bias fades this will become more apparent.
CONCLUSION: Subsequent research has confirmed that underlying
endocannabinoid deficiencies indeed play a role in migraine,
fibromyalgia, irritable bowel syndrome and a growing list of other
medical conditions. Clinical experience is bearing this out. Further
research and especially, clinical trials will further demonstrate the
usefulness of medical cannabis. As legal barriers fall and scientific
bias fades this will become more apparent.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

16. SEVERAL INTERVENTIONS UPREGULATE THE
ECS SYSTEM:
•Analgesics, anti-inflammatories
•Antidepressants, antipsychotics, anxiolytics, anticonvulsants
•Massage and manipulation
•Acupuncture
•Dietary supplements and herbal medicines.
SEVERAL INTERVENTIONS UPREGULATE THE
ECS SYSTEM:
•Analgesics, anti-inflammatories
•Antidepressants, antipsychotics, anxiolytics, anticonvulsants
•Massage and manipulation
•Acupuncture
•Dietary supplements and herbal medicines.
McPartland JM et al. PLoS One. 2014, Mar
12;9(3):e89566
McPartland JM et al. PLoS One. 2014, Mar
12;9(3):e89566
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

17. Way back in April 14-15, 1912
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

18. Purdue University & Mr. Fred A. Miler, botanist to Eli Lilly
& Co. partner for “medicinal extract of Hemp (CBD)
Research,” c. 1912-13
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

19. This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

20. This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

21. Hemp
• One of the oldest known cultivated plants
• 12,000 years of usage
• Used for clothes, soap and rope
• Has a wide array of nutrients in
it of almost all sources.
• Medicinal use: 6,000 years
• 3rd
most prescribed medicinal agent for 60 years
prior to its prohibition in 1937This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

22. Cannabis SATIVA -
HEMP
Cannabis SATIVA - HEMP Cannabis SATIVA
subspecies INDICA
AND SEX DOESN’T MATTER!!
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

23. Endogenous cannabinoids
• Synthesized in OUR body: ENDOcannabinoids
– 2-AG (2-arachidonylgylerol)
– Anadamide (N-arachidonoylethanolamine “AEA”)
• These are fatty acid neurotransmitters
• 2-AG – most abundant endocannabinoid in the
body
• Regulates appetite, immune function, pain signals,
energy storage, among others.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

24. Endocannibinoid system – the body’s
primary tool of homeostasis
• Most significant neurotransmitter system in
the body
• Regulates & balances:
– Nerve function, stress recovery,
inflammation levels, immune function,
energy intake and storage, cell life-
cycles/apoptosis/reproduction,
circulatory system
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

25. The endocanninoid receptors by the
numbers…• CB1
– Brain spinal cord, reproductive & connective tissues
• CB2
– Modulates immune system. Found on spleen, tonsils,
thymus, all white blood cells (receptors)
• T cells, B-eta cells, macrophages
• GPR55 – linked to bone development and cancer
cell proliferation
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

26. Endocannabinoids 101
• YOU make ENDO-cannabinoids
– 2-AG (2 arachidonoylglycerol)
• Most abundant
• Regulates appetite, immune function, pain signals, energy
storage.
– Anandamide (N-arachidonoylethanolamine “AEA”)
• HEMP plant makes PHYTO-cannabinoids
– Interacts well with human CB receptors.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

27. Anandamide
• From Sanskrit for “bliss” or “happiness.”
• Regulates pleasurable activities – food intake,
reproduction, sleep, and pain relief
• Found in mother’s milk, chocolate, and release
during ovulation
• Produced during meditation, yoga, and causes
RUNNER’S HIGH.
• A “bridge” between mind and body.This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

28. This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

29. This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

30. • Circulating eCB’s in humans, dogs, and ferrets measured before and
after treadmill exercise.
• “We show that humans and dogs shaire significantly increased
exercise-induced eCB signaling following high-intensity endurance
running.
• eCB’s are “a neurobiological reward for endurance exercise.”
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

31. CECD: Clinical endocannabinoid
deficiency
• Implicated in many hard-to-treat disease
states:
– Fibromyalgia
– Chronic migraines
– Depression/anxiety
– Irritable bowel syndrome Russo EB. Neuro End Lett
2008 April; 29(2): 192-200.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

32. 60 citations 08 19 2018
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

33. 57 citations 04/06/ 2017“Deficits in signaling mediated by the
endocannabinoid 2-AG have been reported in
mouse models of autism spectrum disorder.”
“Deficits in signaling mediated by the
endocannabinoid 2-AG have been reported in
mouse models of autism spectrum disorder.”
“Deficits in social interaction, excessive grooming,
decreased exploration of environment...”
“Deficits in social interaction, excessive grooming,
decreased exploration of environment...”
“MOA” – “increased glutamatergic drive, which is
consistent with a loss of retrograde feedback
inhibition.”
“MOA” – “increased glutamatergic drive, which is
consistent with a loss of retrograde feedback
inhibition.”
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

34. B
“Endocannabinoid deficiency syndrome” – 2001
•“In certain conditions, whether congenital or
acquired, endocannabinoid tone becomes deficient and
productive of pathophysiological syndromes.”
•many brain disorders are based on deficient
neurotransmitters.
“Endocannabinoid deficiency syndrome” – 2001
•“In certain conditions, whether congenital or
acquired, endocannabinoid tone becomes deficient and
productive of pathophysiological syndromes.”
•many brain disorders are based on deficient
neurotransmitters.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

35. 19 results August 10, 201819 results August 10, 2018
• Stimulating ECS:
• Reduction in alcohol consumption with +ECS input
• Antihyperalgesic activities of EC in Mouse Model of
neuropathic pain
• Effects in migraine, fibromyalgia, irritable bowel, and
“other treatment-resistant syndromes” (Russo EB, 2016)
• CB2 deficient mice have pro-inflammatory obesity
• Stimulating ECS:
• Reduction in alcohol consumption with +ECS input
• Antihyperalgesic activities of EC in Mouse Model of
neuropathic pain
• Effects in migraine, fibromyalgia, irritable bowel, and
“other treatment-resistant syndromes” (Russo EB, 2016)
• CB2 deficient mice have pro-inflammatory obesity

36. “Ethan B. Russo's paper of December 1, 2003
explored the concept of a clinical endocannabinoid
deficiency (CECD) underlying the pathophysiology of
migraine, fibromyalgia, irritable bowel syndrome and
other functional conditions alleviated by clinical
cannabis.”
“Ethan B. Russo's paper of December 1, 2003
explored the concept of a clinical endocannabinoid
deficiency (CECD) underlying the pathophysiology of
migraine, fibromyalgia, irritable bowel syndrome and
other functional conditions alleviated by clinical
cannabis.”“Subsequent research has confirmed that underlying
endocannabinoid deficiencies indeed play a role in
migraine, fibromyalgia, irritable bowel syndrome and
a growing list of other medical conditions.”
“Subsequent research has confirmed that underlying
endocannabinoid deficiencies indeed play a role in
migraine, fibromyalgia, irritable bowel syndrome and
a growing list of other medical conditions.”
Smith SC, Wagner MS. Neuro Endocrinol Letter. 2014;35(3):198-201.

37. Bluett RJ. Central anandamide deficiency predicts stress-induced
anxiety: behavioral reversal through endocannabinoid
augmentation. Transl Psych 2014 Jul 8;4:e 408
• Pharmacological augmentation of central endogenous
cannabinoid (eCB) signaling may be an effective
therapeutic strategy to mitigate the adverse behavioral
and physiological consequences of stress.
• These studies provide further support that eCB-
augmentation is a viable pharmacological strategy
for the treatment of stress-related neuropsychiatric
disorders.
• Pharmacological augmentation of central endogenous
cannabinoid (eCB) signaling may be an effective
therapeutic strategy to mitigate the adverse behavioral
and physiological consequences of stress.
• These studies provide further support that eCB-
augmentation is a viable pharmacological strategy
for the treatment of stress-related neuropsychiatric
disorders.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

38. statistically significant differences in cerebrospinal fluid anandamide
levels have been documented in migraineurs, and advanced imaging
studies have demonstrated ECS hypofunction in post-traumatic stress
disorder. Additional studies have provided a firmer foundation for the
theory, while clinical data have also produced evidence for decreased
pain, improved sleep, and other benefits to cannabinoid treatment and
adjunctive lifestyle approaches affecting the ECS.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

39. Inflammation and CBD
• CBD tested on mice that had a
version of RA
– CBD reduced mouse inflammation
by 50% at correct dosage
– Malfait AM et al. The nonpsychoactive cannabis
constituent cannabidiol is an oral anti-arthritic
therapeutic in murine collagen- induced arthritis.
PNAS vol 97 no 17, 9561-9566
• one dosage of CBD immediately
following a heart attack can reduce
infarct size by c. 66%
– Durst R et al. Am J Physiol Heart Circ
Physiol.2007Dec;293(6): H3602-7.This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

40. B
These data suggest that anandamide blocks
human breast cancer cell proliferation
through CB1-like receptor-mediated
inhibition of endogenous prolactin action
at the level of prolactin receptor.
These data suggest that anandamide blocks
human breast cancer cell proliferation
through CB1-like receptor-mediated
inhibition of endogenous prolactin action
at the level of prolactin receptor.This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

41. B
Both endocannabinoids exhibited
neuroprotective activity at LOWER dose,
but were neurotoxic at higher dose.
Both endocannabinoids exhibited
neuroprotective activity at LOWER dose,
but were neurotoxic at higher dose.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

42. B
CONCLUSIONS. This data shows that acute
administration of CBD reduces resting BP and the
BP increase to stress in humans, associated with
increased HR.
CONCLUSIONS. This data shows that acute
administration of CBD reduces resting BP and the
BP increase to stress in humans, associated with
increased HR.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

43. What does the literature say about…
• Pain
• Sleep
• Anxiety
• Seizures
• IBS
• ADHD
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

44. “Endocannabinoids, a group of less well--known endogenous bioactive lipids ... [are]
able to influence both inflammation and pain.”
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

45. This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

46. This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

47. • are under circadian control
• promote non-rapid eye movement sleep
• promote REM by interacting with melanin-
concentrating hormone neurons
• restores sleep in a model of insomnia in rats
Endocannabinoids sleep – 107 citations 8/22/2018
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

48. • cannabidiol (CBD), while representing a less
specific pharmacological approach, may be another
way to modulate eCBs and interacting
neurotransmitter systems to alleviate anxiety.
Endocannabinoids anxiety– 324 citations
8/22/2018
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

49. This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

50. CONCLUSIONS:
Our findings demonstrate that the deletion of
Dagla [dacylgerol lipase alpha (DAGLalpha)]
adversely affects the emotional state of animals
and results in enhanced anxiety, stress, and fear
responses.
CONCLUSIONS:
Our findings demonstrate that the deletion of
Dagla [dacylgerol lipase alpha (DAGLalpha)]
adversely affects the emotional state of animals
and results in enhanced anxiety, stress, and fear
responses.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

51. Seizures
“These data suggest the need for developing novel
treatments using compounds that selectively target
individual elements of the endocannabinoid signaling
system.
“These data suggest the need for developing novel
treatments using compounds that selectively target
individual elements of the endocannabinoid signaling
system.
93 citations on “endocannabinoid system epilepsy” – 8/22/2018lsdkfj
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

52. Endocannabinoid system and IBS
Hasenoehri C et al. The gastrointestinal tract – a central organ of cannabinoid signaling in
health and disease. Neurogastroenterol. Motil. 2016 Dec; 28(12):1765-1780.
“Cannabinoid receptors and their
endogenous ligands, the endocannabinoids,
participate in the regulation of GI motility,
secretion, and the maintenance of the
epithelial barrier integrity.”
“Cannabinoid receptors and their
endogenous ligands, the endocannabinoids,
participate in the regulation of GI motility,
secretion, and the maintenance of the
epithelial barrier integrity.”
Endocannabinoid system irritable bowel syndrome
– 238citations - 8/22/2018
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

53. ADHD & the Endocannabinoid System
• 18 citations in literature – 8/22/2018
– “adults with ADHD may represent a subgroup of
individuals who experience a reduction of
symptoms and no cognitive impairments
following cannabinoid use.”
• Cooper RE et al. Eur Neuropsychopharmacol. 2017
Aug; 27(8):795-808
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

54. • 30 adults with ADHD, placebo controlled study
• Sativex Oromucosal spray was used.
• “Adults with ADHD may represent a sub-group of
individuals who experience a reduction of symptoms
and no cognitive impairments following cannabinoid
use.”
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

55. Bioavailability problems of
commercial products
• Commercial hemp oil
– Not THC free.
– Only 6% of what is ingested gets absorbed.
– 90% is wasted.
• micellized hemp oil* = 85% bioavailability
– Onset of action drops from 1-2 hours down to 5 – 15 min.
• ultra micellized hemp oil* = 94% bioavailability
* Note = generic, non-branded products are cited
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

56. Full Spectrum Hemp Oil
NOT just CBD…
• Cannabinoids
• Terpenes
• Flavonoids
• Fatty Acids
• Vitamins
• Minerals
7

57. • Inhibits cancer cell
growth
• Neuroprotective
• Grows bone
• Reduces
seizures/convulsions
• Reduces
inflammation
• Relieves pain/anxiety
• Tranquilizing
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

58. Micellation
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

59. Study of one hemp oil at Mayo Clinic
• N = 20
• Up to 94% absorption of cannabinoids in 12 hours
– 10.9 mg of CBD in the hemp oil
– - 8.3 mg back in the blood
• Blood drawn every 15 minutes and then hourly out to 11 hours
• 50% of this hemp oil was in the body in about 20
minutes.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

60. This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

61. • 2000 inappropriate online health
claims; 1000 still online
• www.truthinadvertising.org , 2017
• 158 direct selling companies
• 62 sell nutritional supplements
• 60/62 (97%) have made health claims
that...
• “their products can diagnose, treat,
cure, prevent, or alleviate the
symptoms of and/or reduce the risk of
developing a multitude of diseases.”
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

62. Obligatory disclaimer. These
statements have not been evaluated by
the Food and Drug Administration. This
product is not intended to diagnose,
treat, cure or prevent any disease.
https://extranet.securefreedom.com/Zilis/Personal/Resources/ZilisComplianceTraining.pd
f
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

63. Personal collection
Louis B. Cady,
M.D.
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

64. Thank you for coming!
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.

65. Contact information:
Louis B. Cady, M.D.
www.cadywellness.com
Office: 812-429-0772
E-mail: lcady@cadywellness.com
For appointments: info@cadywellness.com
4727 Rosebud Lane – Suite F
Interstate Office Park
Newburgh, IN 47630 (USA)
This slide deck is not approved by the FDA. No Zilis product can be represented to treat, prevent, mitigate, or cure any disease. They
are used ONLY for the structure and support of the body – specifically, the endocannabinoid system.